SCHEDULE 13G/A: RA Capital Management Affiliates Maintain 8.9% Stake in Dianthus Therapeutics
Beneficial Ownership Disclosure
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Rajeev Shah, have reported a continued beneficial ownership of 8.9% in Dianthus Therapeutics, Inc., holding 2,866,733 shares of common stock as of March 31, 2025.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") beneficially own 2,866,733 shares of Dianthus Therapeutics, Inc. common stock.
- This ownership represents 8.9% of the Issuer's common stock outstanding as of March 31, 2025, based on 32,125,933 shares reported outstanding in the Issuer's Definitive Proxy Statement on Schedule 14A filed on April 10, 2025.
- The shares are primarily held by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P. serving as the investment adviser and exercising shared voting and dispositive power over these securities.
- Peter Kolchinsky and Rajeev Shah, as controlling persons of RA Capital Management GP, LLC (the general partner of RA Capital), are deemed beneficial owners of the securities.
- The Reporting Persons explicitly disclaim status as a "group" for purposes of this Schedule 13G and disclaim beneficial ownership of the securities except for determining their obligations under Section 13(d) of the Act.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's continued stake in the company.
- Company Management: Awareness of a large, active investor's position in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement, reflecting the beneficial ownership stake. |
| 04/10/2025 | Date Dianthus Therapeutics, Inc. filed its Definitive Proxy Statement on Schedule 14A, reporting 32,125,933 shares outstanding. |
| 05/15/2025 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Dianthus Therapeutics, RA Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Healthcare Fund, Peter Kolchinsky, Rajeev Shah
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.